IP Library Granted Patent US 8,889,128
Granted Patent B2
US 8,889,128 · App. 12/518,855 · Granted Nov 18, 2014

Use of the endoglycosidase endos for treating immunoglobulin G mediated diseases

Inventors: Lars Björck (Lund, SE); Mattias Collin (Lund, SE); Arne Olsén (Onsala, SE); Rikard Holmdahl (Lund, SE); Kutty Selva Nandakumar (Tamilnadu, IN); Oonagh Shannon (Veberod, SE)
Assignee: Hansa Medical AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,128
App. No.
12/518,855
Granted
Nov 18, 2014
Kind
B2
Abstract

The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.

Claims (7)

1. A method of treating or preventing a disease or condition mediated by IgG antibodies in a subject in need thereof, wherein the method of treating the disease or condition comprises administering to the subject a therapeutically effective amount of the polypeptide consisting of SEQ ID NO: 1 and wherein the method of preventing the disease or condition comprises administering to the subject a prophylactically effective amount of the polypeptide consisting of SEQ ID NO: 1.

2. A method of treating, ex vivo, blood taken from a patient suffering from a disease or condition mediated by IgG antibodies, comprising contacting the blood with an EndoS polypeptide.

3. A method according to claim 2 , wherein the blood is returned to the patient after contacting it with said EndoS polypeptide.

4. A method of treating or preventing rheumatoid arthritis in a subject in need thereof, wherein the method of treating comprises administering to the subject a therapeutically effective amount of an EndoS polypeptide and wherein the method of preventing comprises administering to the subject a prophylactically effective amount of an EndoS polypeptide.

5. A method of treating or preventing systemic lupus erythematosus in a subject in need thereof, wherein the method of treating comprises administering to the subject a therapeutically effective amount of an EndoS polypeptide and wherein the method of preventing comprises administering to the subject a prophylactically effective amount of an EndoS polypeptide.

6. A method of treating or preventing idiopathic thrombocytopenic purpura in a subject in need thereof, wherein the method of treating comprises administering to the subject a therapeutically effective amount of an EndoS polypeptide and wherein the method of preventing comprises administering to the subject a prophylactically effective amount of an EndoS polypeptide.

7. A method of treating or preventing allograft or xenograft rejection of a transplant in a subject in need thereof, wherein the method of treating comprises administering to the subject a therapeutically effective amount of an EndoS polypeptide and wherein the method of preventing comprises administering to the subject a prophylactically effective amount of an EndoS polypeptide.

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2020
From: HANSA MEDICAL AB
To: HANSA BIOPHARMA AB
Reel/Frame 052002/0992 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2009
From: BJORCK, LARS; COLLIN, MATTIAS; OLSEN, ARNE; HOLMDAHL, RIKARD; NANDAKUMAR, KUTTY SULVA; SHANNON, OONAGH
To: HANSA MEDICAL AB
Reel/Frame 023614/0189 →
Priority Claims (1)
GB 0624874.4 · Dec 13, 2006 · national
Continuity (1)
Related Publication 20100135981A1 · Jun 3, 2010